URGN Q3'26 Earnings: EPS estimate is 0.11 USD

What happened

UroGen Pharma is scheduled to report Q3'26 results on November 4 before the market opens at 8:00 AM ET. Analysts estimate revenue of 89.92 million USD and earnings per share of 0.11 USD.

Confirmed

Global impact / market context

Profit of 0.11 USD per share would contrast with prior quarters' losses. A revenue or profit miss could change how investors value the company's growth prospects and their willingness to hold the stock.

Analyst inference

Past results show revenue estimates missed in the two quarters before the latest one but beat most recently, while profit estimates were mixed. This history suggests estimates carry uncertainty, so actual figures may differ from the 0.11 USD and 89.92 million USD figures.

Analyst inference

What to watch

1. Watch whether reported revenue and earnings per share match the 89.92 million USD and 0.11 USD estimates when results arrive on November 4. Confirmed
2. Watch whether the company gives any details on future revenue or spending plans, which could show how it intends to grow beyond this quarter. Proposed
3. Watch how the reported numbers compare with past surprises, since estimates missed in the two quarters before the latest one, which may signal risk of another miss. Analyst inference

Evidence

• Original source link unavailable